In this article, we will discuss Olaparib (Description-3). So, let’s get started.
Olaparib is available as a tablet and capsule formulation. The oral bioavailability of the tablet formulation is higher than the capsule formulation. Population pharmacokinetic analyses have shown that
the steady state exposure (AUC) following 300 mg tablet twice daily was 77% higher compared to that following 400 mg capsule twice daily. The olaparib geometric mean AUC and Cmax following a single 300 mg tablet dose were 42.0 μg*h/mL (n = 204) and 5.8 μg/mL (n = 204), respectively, and the steady state geometric mean AUC and Cmax following 300 mg tablet twice daily were 49.0 μg*h/mL (n = 227) and 7.7 μg/mL (n = 227), respectively. Olaparib showed time-dependent PK that the steady state clearance decreased by 15% after multiple dosing.